Cero Therapeutics Holdings, Inc. Files 8-K
Ticker: CEROW · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1870404
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
Cero Therapeutics (fka Phoenix Biotech) filed an 8-K on 11/18, reporting events from 11/15.
AI Summary
Cero Therapeutics Holdings, Inc. filed an 8-K on November 18, 2024, reporting on events as of November 15, 2024. The filing indicates the company's former name was Phoenix Biotech Acquisition Corp., with a name change effective June 30, 2021. The report includes financial statements and exhibits.
Why It Matters
This 8-K filing provides an update on Cero Therapeutics Holdings, Inc., including its former identity as Phoenix Biotech Acquisition Corp., which may be relevant for investors tracking the company's history and corporate actions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting corporate information and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- Phoenix Biotech Acquisition Corp. (company) — Former company name
- November 15, 2024 (date) — Date of earliest event reported
- November 18, 2024 (date) — Date of report
- June 30, 2021 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for Cero Therapeutics Holdings, Inc.?
The primary purpose is to report on "Other Events" and "Financial Statements and Exhibits" as of November 15, 2024.
What was Cero Therapeutics Holdings, Inc. previously known as?
Cero Therapeutics Holdings, Inc. was formerly known as Phoenix Biotech Acquisition Corp.
When did the name change from Phoenix Biotech Acquisition Corp. to Cero Therapeutics Holdings, Inc. occur?
The name change occurred on June 30, 2021.
What is the SIC code for Cero Therapeutics Holdings, Inc.?
The Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
In which state was Cero Therapeutics Holdings, Inc. incorporated?
Cero Therapeutics Holdings, Inc. was incorporated in Delaware.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-18 08:00:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
Filing Documents
- ea0221421-8k_cerothera.htm (8-K) — 27KB
- ea022142102ex99-1_cero.htm (EX-99.1) — 10KB
- 0001213900-24-099354.txt ( ) — 255KB
- cero-20241115.xsd (EX-101.SCH) — 4KB
- cero-20241115_def.xml (EX-101.DEF) — 26KB
- cero-20241115_lab.xml (EX-101.LAB) — 36KB
- cero-20241115_pre.xml (EX-101.PRE) — 25KB
- ea0221421-8k_cerothera_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On November 15, 2024, the Company, issued a press release announcing that the U.S. Food and Drug Administration had cleared the Company's Investigational New Drug Application for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML). A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. Item9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press release, dated November 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 18, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Interim Chief Executive Officer 2